Semaglutide helps 4 in 10 children with obesity lose weight, move below limit in new trial

About four in 10 children with obesity who received once-weekly semaglutide were no longer classified as having obesity after 68 weeks, according to topline results from a phase 3 trial released by Novo Nordisk.